379 related articles for article (PubMed ID: 35152997)
1. Strategies for manufacturing cell therapy products aligned with patient needs.
Guha P; Katz SC
Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
[TBL] [Abstract][Full Text] [Related]
2. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
3. Platforms for Clinical-Grade CAR-T Cell Expansion.
Mizukami A; Swiech K
Methods Mol Biol; 2020; 2086():139-150. PubMed ID: 31707673
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
5. Bright future or blind alley? CAR-T cell therapy for solid tumors.
Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
[TBL] [Abstract][Full Text] [Related]
6. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
7. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
8. Overcoming Challenges in Process Development of Cellular Therapies.
Highfill SL; Stroncek DF
Curr Hematol Malig Rep; 2019 Aug; 14(4):269-277. PubMed ID: 31278568
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
11. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
12. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
13. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
14. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
15. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
[TBL] [Abstract][Full Text] [Related]
16. A guide to manufacturing CAR T cell therapies.
Vormittag P; Gunn R; Ghorashian S; Veraitch FS
Curr Opin Biotechnol; 2018 Oct; 53():164-181. PubMed ID: 29462761
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
18. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
19. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
20. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]